Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry-Comparison of Three Different GPA Prognostic Scores
Standard
Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry-Comparison of Three Different GPA Prognostic Scores. / Riecke, Kerstin; Müller, Volkmar; Weide, Rudolf; Schmidt, Marcus; Park-Simon, Tjoung-Won; Möbus, Volker; Mundhenke, Christoph; Polasik, Arkadius; Lübbe, Kristina; Hesse, Tobias; Laakmann, Elena; Thill, Marc; A Fasching, Peter; Denkert, Carsten; Fehm, Tanja; Nekljudova, Valentina; Rey, Julia; Loibl, Sibylle; Witzel, Isabell.
in: CANCERS, Jahrgang 13, Nr. 4, 844, 17.02.2021.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry-Comparison of Three Different GPA Prognostic Scores
AU - Riecke, Kerstin
AU - Müller, Volkmar
AU - Weide, Rudolf
AU - Schmidt, Marcus
AU - Park-Simon, Tjoung-Won
AU - Möbus, Volker
AU - Mundhenke, Christoph
AU - Polasik, Arkadius
AU - Lübbe, Kristina
AU - Hesse, Tobias
AU - Laakmann, Elena
AU - Thill, Marc
AU - A Fasching, Peter
AU - Denkert, Carsten
AU - Fehm, Tanja
AU - Nekljudova, Valentina
AU - Rey, Julia
AU - Loibl, Sibylle
AU - Witzel, Isabell
PY - 2021/2/17
Y1 - 2021/2/17
N2 - Several scores have been developed in order to estimate the prognosis of patients with brain metastases (BM) by objective criteria. The aim of this analysis was to validate all three published graded-prognostic-assessment (GPA)-scores in a subcohort of 882 breast cancer (BC) patients with BM in the Brain Metastases in the German Breast Cancer (BMBC) registry. The median age at diagnosis of BM was 57 years. All in all, 22.3% of patients (n = 197) had triple-negative, 33.4% (n = 295) luminal A like, 25.1% (n = 221) luminal B/HER2-enriched like and 19.2% (n = 169) HER2 positive like BC. Age ≥60 years, evidence of extracranial metastases (ECM), higher number of BM, triple-negative subtype and low Karnofsky-Performance-Status (KPS) were all associated with worse overall survival (OS) in univariate analysis (p < 0.001 each). All three GPA-scores were associated with OS. The breast-GPA showed the highest probability of classifying patients with survival above 12 months in the best prognostic group (specificity 68.7% compared with 48.1% for the updated breast-GPA and 21.8% for the original GPA). Sensitivities for predicting 3 months survival were very low for all scores. In this analysis, all GPA-scores showed only moderate diagnostic accuracy in predicting the OS of BC patients with BM.
AB - Several scores have been developed in order to estimate the prognosis of patients with brain metastases (BM) by objective criteria. The aim of this analysis was to validate all three published graded-prognostic-assessment (GPA)-scores in a subcohort of 882 breast cancer (BC) patients with BM in the Brain Metastases in the German Breast Cancer (BMBC) registry. The median age at diagnosis of BM was 57 years. All in all, 22.3% of patients (n = 197) had triple-negative, 33.4% (n = 295) luminal A like, 25.1% (n = 221) luminal B/HER2-enriched like and 19.2% (n = 169) HER2 positive like BC. Age ≥60 years, evidence of extracranial metastases (ECM), higher number of BM, triple-negative subtype and low Karnofsky-Performance-Status (KPS) were all associated with worse overall survival (OS) in univariate analysis (p < 0.001 each). All three GPA-scores were associated with OS. The breast-GPA showed the highest probability of classifying patients with survival above 12 months in the best prognostic group (specificity 68.7% compared with 48.1% for the updated breast-GPA and 21.8% for the original GPA). Sensitivities for predicting 3 months survival were very low for all scores. In this analysis, all GPA-scores showed only moderate diagnostic accuracy in predicting the OS of BC patients with BM.
U2 - 10.3390/cancers13040844
DO - 10.3390/cancers13040844
M3 - SCORING: Journal article
C2 - 33671376
VL - 13
JO - CANCERS
JF - CANCERS
SN - 2072-6694
IS - 4
M1 - 844
ER -